HBM contact: Dr Emil Bujak
Company status: private
Therapeutics, is an early stage biotech company focused on discovering and
developing innovative small molecule oncology medicines to help patients with
unmet medical needs. NiKang’s discovery approach is informed by target
structure biology and capitalizes on structure-based drug design enabling a
rapid and efficient discovery and development of proprietary drug candidates
with the most desirable pharmacological features into clinical studies.